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Ricinoleic acidIn the work, the in vitro antiproliferative activity of a series of synthetic fatty acid amides were investi-
gated in seven cancer cell lines. The study revealed that most of the compounds showed antiproliferative
activity against tested tumor cell lines, mainly on human glioma cells (U251) and human ovarian cancer
cells with a multiple drug-resistant phenotype (NCI-ADR/RES). In addition, the fatty methyl benzylamide
derived from ricinoleic acid (with the fatty acid obtained from castor oil, a renewable resource) showed a
high selectivity with potent growth inhibition and cell death for the glioma cell line—the most aggressive
CNS cancer.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
In recent years, considerable efforts have been made to develop
novel drugs for cancer treatment. Cancer is a major public health
problem in both developed and developing countries, and it is
the second leading cause of death in the United States. Annual esti-
mates show an alarming increase of new cases worldwide.1 The
disease is characterized by the uncontrolled division and prolifer-
ation of cells, which can be caused, among other mechanisms, by
DNAmutations, cell cycle defects, and deregulated apoptosis; com-
pounds that induce apoptosis may be useful as targeted cancer
therapies.2,3 In addition, multidrug resistance (MDR) is the princi-
pal mechanism by which many cancers, such as breast, ovarian,
lung among others, develop resistance to antitumor drugs,4,5 and
new drugs that can overcome this obstacle are important goals of
anticancer studies.
Fatty acid amides (Fig. 1) are considered a new family of biolog-
ically important lipids as shown by different biochemical and phar-
macological studies,6,7 and they are part of the endocannabinoid
family.8 Studies with synthetic fatty acid amides showed antipro-
liferative activity against several tumor cells, suggesting that vari-
ation in the fatty acid moieties on groups attached to the nitrogenatom may be responsible for differences in antiproliferative pro-
ﬁles.9–11 The effect of endocannabinoids and fatty acid amides in
cancer cell proliferation was reported by the binding to cannabi-
noids and vanilloids receptors.2,12,13
Previously, we reported the synthesis and antituberculosis
activity of new fatty acid amides and the fatty acid isoniazid, and
we demonstrated that the fatty acid chain is of fundamental
importance to biological activity, most likely by facilitating its per-
meability in bacterial cells.14,15 To continue our efforts to discover
fatty acid molecules with improved therapeutic potential, we eval-
uated the in vitro antiproliferative activity of a series of amide
derivatives of long-chain fatty acids in different tumor cell lines.
2. Results and discussion
The fatty acid amides were readily obtained by the synthetic
pathway shown in Figure 214–17 and were subjected to an
in vitro antiproliferative study using a panel of seven human can-
cer cell lines—glioma (U251), breast epithelial carcinoma (MCF-7),
ovarian with a phenotype of multiple drug resistance (NCI-ADR/
RES), kidney (786-0), non-small cell lung cancer (NCI-H460), pros-
tate (PC-3), ovarian (OVCAR-3)—as well as one non-tumor cell line,
human keratinocyte (HaCaT), and kidney epithelial cells from the
African green monkey (VERO). The chemotherapeutic agent
doxorubicin was used as a standard positive control.
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Figure 1. Fatty acid amides biologically actives.
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Figure 2. Fatty acid amides evaluated for antiproliferative activity on several cell lines.
Table 1
GI50 values of fatty acid amides against several cell lines
Amide Tumor cell line Mean GI50 Non-tumor cell lineb
U251 MCF-7 NCI-ADR/RES 786-0 NCI-H460 PC-3 OVCAR-3
GI50a (lg mL1)
1a — — — — — — — — —
1c 55.4 53.4 50.3 104.4 94.9 106.9 103.2 92.0
(R)-1d 8.6 37.8 8.6 32.3 32.3 122.6 31.6 39.1 30.8
(R)-2b 160.6 0.06 25.7 — — — — — —
(R)-2c 6.1 6.1 3.0 26.8 36.6 46.9 56.9 26.5 10.3c
(S)-3b — — — — — — — — 69.5
(S)-3c 5.1 7.17 0.3 10.3 15.2 13.7 10.5 8.8 6.4
(R,S)-3d 3.6 5.1 1.9 6.7 8.3 11.7 11.1 6.9 9.7
(S)-3e 0.7 5.3 3.0 3.2 6.1 6.8 3.5 4.0 1.3
(S)-3f — 110.2 — — — — 21.7 — 24.6
4a — — 157.7 — — — — — —
4b 116.9 129.5 157.7 — — 75.6 157.7 — 117.7
4c 27.3 25.9 9.1 35.4 36.5 16.9 35.4 26.6 14.4
(R)-4d 3.6 6.5 2.8 6.6 4.1 6.3 4.1 4.8 3.4c
5a 4.6 4.6 4.6 5.5 5.9 4.7 6.3 5.2 4.8
5b 8.0 7.4 7.1 14.0 10.8 9.4 7.3 9.1 6.3
5c 3.8 5.2 0.2 5.2 45.6 13.0 11.5 12 3.9c
(R)-5d 1.5 4.4 4.0 4.1 6.9 6.2 4.3 4.4 4.0c
5e 4.2 4.2 4.7 4.7 7.0 4.7 5.7 5.0 13.7c
6c 6.7 7.6 7.7 10.6 23.0 8.7 9.3 10.5 7.7
(R)-6d 14.8 6.3 22.7 24.2 10.7 23.3 16.6 16.9 2.6
6e 44.2 22.1 63.2 58.4 29.1 53.6 48.9 45.6 4.2
7a 25 15.4 6.2 33.1 34.1 22.2 33.1 24.1 28.9
7b 39.9 42.8 33.1 41.1 53.1 41.1 43.3 42.0 41.5
7c 2.8 4.9 3.3 4.5 7.9 5.2 4.9 4.7 5.3
(R)-7d 33.1 41.8 29.4 36.0 49.1 38.5 31.0 37 41.3
a GI50 = 50% inhibition of cell growth.
b Non-tumor cell line = HaCat.
c Non-tumor cell line = VERO.
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was given by three parameters for each cell line: GI50 (concentra-
tion which inhibits 50% cell growth), TGI (concentration for total
inhibition of cell growth) and LC50 (concentration which leads to
50% cell death), calculated by origin 9.1 software. The dose–
response curves for all synthesized compounds against the tested
cell lines are given in the Supplementary material.
First, the data were analyzed in terms of the GI50 values
(Table 1). For this parameter, compounds with GI50 values lower
than 30 lg mL1 were considered to be active. Most of the com-
pounds were active against most of the cell lines tested, in aTable 2
Growth inhibition effect of the fatty acid benzylamide series 1–3 on several cell lines
Amide Tumor cel
U251 MCF-7 NCI-ADR/RES 786-
TGIa (lg m
O
N
H
( )14
1a
>250 >250 >250 >250
O
N
H
( )7( )7
1c
>250 >250 >250 >250
O
N
H
( )7( )5
OH
(R)-1d
47.5 104.5 46.6 71
O
N
H
( )16
(R)-2b
>250 >250 >250 >250
O
N
H
( )7( )7
(R)-2c
28.3 40.8 35.3 84
O
N
H
( )16
(S)-3b
>250 >250 >250 >250
O
N
H
( )7( )7
(S)-3c
17.8 43.0 7.1 45
O
N
H
( )7( )5
OH
(R,S)-3d
13.9 84.5 >250 60
O
N
H
( )7( )4
(S)-3e
5.1 38.6 16.4 7
O
N
H
( )7( )6
(S)-3f
>250 >250 >250 >250
Doxorubicin 0.92 3.3 1.6 >25
a TGI = total growth inhibition.
b Non-tumor cell line = HaCat.
c Non-tumor cell line = VERO.dose-dependent manner. The compounds with the lowest values
were 5c (GI50 = 0.2 lg mL1) and (S)-3c (GI50 = 0.3 lg mL1), fol-
lowed by compound (R,S)-3d (GI50 = 1.9 lg mL1).
To ﬁnd a structure–activity relationship (SAR), we evaluated the
fatty acid amides in terms of the TGI values. Here, the compounds
were arranged into three sets according to the fragment attached
to the nitrogen atom: (1) benzylamine derivatives (Table 2), (2)
ethanolamine derivatives (Table 3) and (3) heterocyclic amine
derivatives (Table 4).
In Table 2, the antiproliferative activities of the benzylamine
derivatives are shown. The derivatives encompass benzylaminel line Mean TGI Non-tumor cell lineb
0 NCI-H460 PC-3 OVCAR-3
L1)
>250 >250 >250 >250 >250
>250 >250 >250 >250 >250
.5 178.8 122.6 86.0 95.5 66.5
>250 >250 >250 >250 >250
.8 105.6 161.6 >250 >100.9 43.0c
>250 >250 >250 >250 >250
.8 49.3 47.1 45.5 44.5 36.8
.1 132.1 141.9 >250 >133.2 59.1
.7 38.9 30.0 20.0 22.4 77.2
>250 >250 >250 >250 >250
4.9 11.7 7.6 7.9 4.1c
2.3
Table 3
Growth inhibition effect of the fatty acid ethanolamides 4a–d on several cell lines
Amide Tumor cell line Mean TGI Non-tumor cell lineb
U251 MCF-7 NCI-ADR/RES 786-0 NCI-H460 PC-3 OVCAR-3
TGIa (lg mL1)
O
N
H
OH( )14
4a
>250 >250 >250 >250 >250 >250 >250 >250 >250
O
N
H
( )16
OH
4b
>250 >250 >250 >250 >250 >250 >250 >250 >250
O
N
H
OH( )7( )7
4c
51.3 66.7 39.5 64.6 81.0 44.2 71.7 59.9 53.5
O
N
H
OH( )7( )5
OH
(R)-4d
6.5 3.7 5.4 20.4 9.8 23.5 8.8 11.2 7.6c
Doxorubicin 0.92 3.3 1.6 >25 4.9 11.7 7.6 7.9 4.1c
2.3
a TGI = total growth inhibition.
b Non-tumor cell line = HaCat.
c Non-tumor cell line = VERO.
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amine (series 3). A clear structure-activity relationship was
observed, as the various changes in the molecules inﬂuence its
activity against the tested cell lines.
In this set, the structurally simplest compound, a benzylamine
with a saturated fatty chain derivative (1a) was totally inactive
(mean TGI >250 lg mL1). The introduction of an unsaturation in
the fatty chain (cis-1c) or a methyl group in the benzylic position
(R-2a, and S-3b) had no inﬂuence on activity (mean TGI
>250 lg mL1), regardless of the conﬁguration of the stereogenic
center.
The derivative 1d, with a hydroxyl functional group in the
monounsaturated chain, showed a potential antiproliferative
(mean TGI 95.5 lg mL1). It seems that functionalization of mono-
unsaturated benzylamide derivatives is necessary for antiprolifer-
ative activity. Comparing with derivative 1d, compounds (R)-2c
and (S)-3c, with a methyl group in the benzylic position and a
monounsaturated fatty chain, showed a lower to higher potential
antiproliferative, respectively (mean TGI >100.9 lg mL1 and
44.5 lg mL1, respectively). In this instance, it was observed that
the spatial orientation of the methyl group has a great inﬂuence
on activity because, in terms of mean TGI, compound (S)-3c was
twice more active than (R)-2c. These results suggest that the unsat-
urated chain was an important fragment only when coupled with a
stereogenic center in the benzylic position or a hydroxyl group in
the fatty chain.
Compound 3d contains all the structural requirements for activ-
ity observed so far: an unsaturated chain coupled with a stereogen-
ic center with S conﬁguration in the benzylic position, and a
hydroxyl group in the monounsaturated fatty chain. Comparing
the derivative 3d to its analogue 3c, which lacks a hydroxyl group,
reveals a mean TGI for 3c that is three times lower than that of 3d
(Mean TGI >133.2 lg mL1 vs 44.5 lg mL1, respectively). How-
ever, comparing the derivative 3d with the analogue 1d, which
lacks a methyl group, showed a smaller decrease in mean TGI
(mean TGI >133.2 lg mL1 vs 95.5 lg mL1, respectively).
The compound 3e contains one additional unsaturation in the
fatty chain, substituting the hydroxyl group (3d), and this com-
pound showed the best mean TGI value (22.4 lg mL1), which issix times more active than the hydroxyl analogue 3d (Mean TGI
>133.2 lg mL1) and twice as active as the monounsaturated ana-
logue 3c (Mean TGI = 44.5 lg mL1).
These data suggest that in the benzylamide series 1, 2, and 3, a
monounsaturated fatty acid along with a methyl group in the ben-
zylic position and a hydroxyl group attached to the fatty chain is
important for antiproliferative activity to a greater or lesser extent,
and an additional unsaturation in the fatty chain caused a substan-
tial drop in mean TGI.
Finally, the double bound conﬁguration was evaluated and was
seen that the change of the conﬁguration from cis (3c) to trans (3f)
caused a total loss of antiproliferative activity.
Analysis of compounds derived from ethanolamine (Table 2,
series 4) showed that substitution of a saturated fatty chain (com-
pounds 4a, b) with a monounsaturated chain (compound 4c)
improved the antiproliferative activity from undetectable (mean
TGI >250 lg mL1, 4a) to some potential antiproliferative (mean
TGI = 59.9 lg mL1, 4c). This activity increased even further when
a hydroxyl group was introduced to the monounsaturated fatty
chain (mean TGI = 11.2 lg mL1, compound 4d). Thus, in this ser-
ies, it again appears that the presence of a hydroxyl group is impor-
tant for antiproliferative activity when associated with an
unsaturated chain.
For compounds in Table 3, it was observed that the presence of
a ﬁve-member heterocyclic compound (series 5) resulted in signif-
icantly greater antiproliferative activity compared with saturated
chain analogues (series 4). Moreover, changing the fatty chain from
C16:0 (5a) to C18:0 (5b) resulted in a reduction in the mean anti-
proliferative activity (from 19.9 mg mL1 for 5a, to 46.5 lg mL1
for 5b), whereas replacing the saturated chain with a monounsat-
urated chain (5c) further reduced the mean antiproliferative activ-
ity (from 46.5 lg mL1 for 5b, to >67.7 lg mL1 for 5c). The
presence of a second double bond in the fatty acid chain (5e)
resulted in increased potency (mean TGI = 24.6 lg mL1), and the
presence of a hydroxyl group in the monounsaturated fatty chain
resulted in the best observed mean antiproliferative activity (mean
TGI = 4.5 lg mL1 for 5d).
To evaluate the inﬂuence of heterocyclic ring size on antiprolif-
erative activity, we changed the ﬁve-member ring (Table 3, series
Table 4
Growth inhibition effect of the fatty acid heterocyclic amide series 5–7 on several cell lines
Amide Tumor cell line Mean TGI Non-tumor cell lineb
U251 MCF-7 NCI-ADR/RES 786-0 NCI-H460 PC-3 OVCAR-3
TGIa (lg mL1)
O
N( )14
5a
11.4 13.2 30.0 16.1 33.5 12.2 22.9 19.9 12.9
O
N( )16
5b
32.5 39.9 43.5 48.4 56.8 36.0 68.5 46.5 27.4
O
N( )7( )7
5c
5.8 >250 5.6 23.3 153.1 21.9 14.0 >67.7 10.6c
O
N( )7( )5
OH
(R)-5d
4.4 1.5 4.0 6.9 6.2 4.3 4.1 4.5 6.8c
O
N( )7( )4
5e
12.0 27.5 7.7 21.9 36.6 32.6 33.9 24.6 45.1c
O
N( )7( )7
6c
25.0 33.3 47.4 40.7 40.7 31.8 35.4 36.3 47.9
O
N( )7( )5
OH
(R)-6d
6.3 14.8 22.7 10.7 23.3 16.6 24.2 16.9 12.8
O
N( )7( )4
6e
22.1 44.2 63.2 29.1 53.6 48.9 58.4 45.6 30.5
O
N( )14
O
7a
55.9 54.7 70.3 69.9 91.0 36.7 72.7 64.5 73.7
O
N( )16
O
7b
82.6 81.7 86.9 85.6 160.8 102.4 111.1 101.6 94.2
O
N( )7( )7
O
7c
6.6 13.1 10.6 11.2 34.7 14.8 13.9 15.0 23.2
O
N( )7( )5
OH
O
(R)-7d
54.5 115.6 142.8 75.7 152.4 72.6 62.2 96.5 97.4
Doxorubicin 0.92 3.3 1.6 >25 4.9 11.7 7.6 7.9 4.1c
2.3
a TGI = Total Growth Inhibition.
b Non-tumor cell line = HaCat.
c Non-tumor cell line = VERO.
344 D.S. dos Santos et al. / Bioorg. Med. Chem. 23 (2015) 340–3475) to a six-member ring (Table 3, series 6). However, a consequent
improvement in mean antiproliferative activity was only observed
with the monounsaturated compound (mean TGI >67.7 lg mL1
for 5c compared with 36.3 lg mL1 for 6c). Analysis of the com-pounds showed that the presence of one or two double bonds in
the fatty acid chain resulted in a similar antiproliferative proﬁle
(mean TGI = 36.3 and 45.6 lg mL1 for 6c and 6e, respectively).
In addition, the presence of a hydroxyl group in the monounsatu-
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Figure 4. Dose–response analysis of cell growth inhibition by compound 5e against
several cell lines.
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(mean TGI 16.9 lg mL1, 6d).
The exchange of a carbon atom with an oxygen atom in the six-
member ring (Table 3, series 7) caused a worsening in mean anti-
proliferative activity when compounds 7a, 7b, and 7d were com-
pared with compounds 5a, 5b, 5d, and 6d. However, when this
oxygenated six-member ring was associated with a monounsatu-
rated fatty chain, its mean antiproliferative activity improved
(mean TGI = 15.0 lg mL1 for 7c) compared with that of 5c (mean
TGI >67.7 lg mL1) and 6c (mean TGI = 36.3 lg mL1).
These data suggest that the antiproliferative activity is inﬂu-
enced by the structural variation in the fatty acid amides, including
both the fatty acid derivative moiety and the moiety attached to
the nitrogen atom.
The data in Tables 2–4 shows that most of the fatty acid amides
studied showed activity against most of the cell lines, with a broad
spectrum inhibition proﬁle, and therewere varied signiﬁcant differ-
ences in cell selectivity and safety. Among the benzylamide deriva-
tives (series 1–3), based on themean TGI, ﬁve compounds showed a
potential antiproliferative: 1d, (R)-2c, (S)-3c, (R,S)-3d, and (S)-3e.
Among these, compounds (S)-3c and (S)-3ewere noted for exhibit-
ing the lowest mean TGI values. Furthermore, compound (S)-3c
showed high activity and selectivity for ovarian cancer cells with
a phenotype of multiple drug resistance (NCI-ADR/RES,
TGI = 7.1 lg mL1) and glioma cell lines (U251, TGI = 17.8 lg mL1),
as well as a favorable safety proﬁle when compared with non-
tumor cells (HaCat, TGI = 36.8 lg mL1). In contrast, compound
(S)-3e showed high activity for glioma cells (U251, TGI =
5.1 lg mL1), prostate cancer cells (PC-3, TGI = 7.7 lg mL1) and
the resistant ovarian cancer cells (NCI-ADR/RES, TGI =
16.4 lg mL1) cell lines but with relative selectivity and a favorable
safety proﬁle when compared with a non-tumor cell line (HaCat,
TGI = 77.2 lg mL1). However, compound (R,S)-3d, derived from
ricinoleic acid and methyl benzylamine, showed good growth inhi-
bition and cell death for the glioma cell line (U251, TGI =
13.9 lg mL1, LC50 = 63.6), with a high degree of selectivity and a
favorable safety proﬁle when compared with a non-tumor cell line
(VERO, TGI = 59.1 lg mL1). The dose–response analysis of cell
growth inhibition by compound (R,S)-3d is displayed in Figure 3.
The ethanolamine derivative (R)-4d showed an excellent mean
TGI, with growth inhibition and death for most of the cell lines, but
with relative selectivity. Furthermore, no favorable safety proﬁleU251
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Figure 3. Dose–response analysis of cell growth inhibition by compound (R,S)-3d
against several cell lineswas observed when a comparison was made with a non-tumor cell
line (VERO, TGI = 7.6 lg mL1).
Among the heterocyclic derivatives, two compounds were efﬁ-
cacious in inhibiting the proliferation of more than one cell line:
compound 5c, which demonstrated speciﬁcity of action in glioma
(U251, TGI = 5.8 lg mL1), ovarian cancer cells with an MDR phe-
notype (NCI-ADR/RES, TGI = 5.6 lg mL1) and another ovarian can-
cer cell line (OVCAR-3, TGI = 14.0 lg mL1), as well as causing cell
death to glioma cells (U251, LC50 = 14.2); and compound 5e, which
was speciﬁc for glioma (U251, TGI = 12.0 lg mL1), and ovarian
cancer cells with an MDR phenotype (NCI-ADR/RES, TGI =
7.7 lg mL1) and caused cell death to glioma cells (U251,
LC50 = 44.4). Although there was loss of both potency and speciﬁc-
ity of action with an additional unsaturation in the fatty acid chain,
compound 5e appeared to have a more favorable safety proﬁle
than that of compound 5c, as it yielded the greatest difference of
activity between tumor and non-tumor cell lines (VERO,
TGI = 45.1 and 10.6 lg mL1, respectively). The dose–response
analysis of cell growth inhibition by compound 5e is displayed in
Figure 4. Ovarian cancer is difﬁcult to diagnose, and recurrence
may occur through multidrug resistance. Both compounds 5c and
5e showed a better potency for ovarian cancer cells with an MDR
phenotype than for native ovarian cancer cells, a very relevant
result given the importance of the search of new drugs for cancers
with MDR.
Among all tested compounds, compound (R)-5d showed the
best mean TGI value, exhibiting growth inhibition and cell death
for most of the lines but without selectivity. This compound
appears to have a general cytotoxic effect.
The morfolyl amine derivative 7c showed a good mean TGI,
with growth inhibition for the most of cell lines, but with relatively
good selectivity and a moderately favorable safety proﬁle when
comparing tumor and non-tumor cell lines.
3. Conclusions
In conclusion, the work presented herein demonstrates that
several fatty acid amides exhibited potent and selective antiprolif-
erative activity in the cancer cell lines tested. In general, benzyla-
mide derivatives showed a clear structure-activity relationship,
with an interesting activity proﬁle when there was a hydroxyl
group in the fatty chain and/or a methyl group in the benzylamino
moiety, as well as an unsaturated chain. For the other derivatives,
the results of the growth inhibition assay demonstrate that TGI is
346 D.S. dos Santos et al. / Bioorg. Med. Chem. 23 (2015) 340–347greatly inﬂuenced by structural modiﬁcations of the fatty acid
amides, in particular, both the fatty acyl chain and the amino-con-
taining moieties of the molecule. Compound (R,S)-3d showed a
high selectivity with potent growth inhibition and cell death for
the glioma cell line—the most aggressive CNS cancer. Also, com-
pound 5e, which was speciﬁc for glioma cells and ovarian cancer
cells with an MDR phenotype, with good antiproliferative poten-
tial. Both compounds showed a favorable safety proﬁle when ana-
lyzing their effects on a non-tumor cell line, and they can serve as
templates for the development of candidate antitumor drugs,
including those for cancers with MDR. Future studies with fatty
acid amides are needed to conﬁrm these important observations.
4. Experimental
4.1. Apparatus and chemistry
Reagents and fatty acids were purchased from Aldrich Chemical
Co. and used without further puriﬁcation. Ricinoleic acid (cis-
C18:1,12-OH) was obtained from castor oil or castor oil biodiesel
hydrolysis. Column chromatography was performed with Silica
Gel 60 A (ACROS Organics 0.035–0.070 mesh). Analytical thin-layer
chromatography was performed with plates containing silica gel
(Merck 60GF245), and the spots were visualized using iodine.
Yields refer to chromatographically and spectroscopically homoge-
neous materials. Melting points were obtained with a Fisatom
430D apparatus and are uncorrected. The NMR spectra were
recorded on a Varian VNMRS 300 MHz spectrometer (1H,
300 MHz and 13C, 75.5 MHz—Universidade Federal do Rio Grande
do Sul, UFRGS, Brazil) in deuterochloroform (CDCl3) solution. The
chemical shift data are reported in units of d (ppm) downﬁeld from
tetramethylsilane (TMS), which was used as an internal standard.
Coupling constants (J) are reported in hertz (Hz) and refer to appar-
ent peak multiplicities. GC/MS analysis was used to ascertain the
purity of all compounds for which biological data was determined
using a GCMS-QP2010Plus chromatographic system (Shimadzu)
equipped with a split/splitless injector coupled with a mass
detector.
4.2. Synthesis
All compounds used in this work were synthesized according to
a published method. Amides 1–3 were synthesized by reacting the
respective fatty acid (0.3 mmol) with amines (0.3 mmol), triethyl-
amine (0.3 mmol), and a catalytic amount of (dimethylamino)pyr-
idine (DMAP), and dicyclohexyl carbodiimide (DCC, 0.3 mmol) in
CH2Cl2 was added dropwise to the above reaction mixture, which
was then stirred at room temperature for 24 h. The solid dicyclo-
hexylurea formed was removed by ﬁltration and the solvent was
evaporated under reduced pressure. Amides 4–7 were synthesized
from fatty acid methyl esters (FAMEs) obtained via esteriﬁcation of
the respective fatty acid. The aminolysis reaction of FAMEs
(0.3 mmol) was realized in the presence of the amines (1.8 mmol)
and acetonitrile for 24 h. The progress of the reactions was moni-
tored by silica gel TLC. The raw products were puriﬁed via column
chromatography on silica gel (n-hexane/ethyl acetate, 7:3) and
analyzed by proton and carbon NMR IR, and ESI–MS/MS. The pre-
sented spectroscopic data are in agreement with the literature.14,15
4.2.1. (S)-Elaidyl methylbenzylamide (3f)
C26H43NO. MW 385.33 g mol1. White solid. Yield 69%. mp
74 C. Rf 0.5 (n-hexane/ethyl acetate, 7:3). 1H NMR (300 MHz,
CDCl3) d 7.3 (m, 5H), 6.0 (sl, 1H), 5.4 (m, 2H), 5.15 (m, 1H), 2.2 (t,2H), 1.98 (m, 4H), 1.64 (m, 1H), 1.51 (d, 3H), 1.29 (m, 23H), 0.9
(t, 3H). 13C NMR (75 MHz, CDCl3) d 172.5 (C@O), 143.2; 130.2;
128.6; 127.3; 76.7; 48.7; 36.7; 32.6; 31.9; 28.9; 25.8; 22.7; 21.7;
14.2. MS [m/z(%)] 385 (M+, 5), 163 [–CH2C(OH)NHCH(CH3)Ph, 40],
120 [–NHCH(CH3)Ph, 40], 105 [–C(CH3)Ph, 100].
4.3. In vitro antiproliferative activity assay
The in vitro antiproliferative activity assay was performed as
described by Monks et al. (1991).18 Seven human tumor cell lines
[U251 (glioma), MCF-7 (breast), NCI-ADR/RES (multiple drug-resis-
tant ovarian cancer cells), 786-0 (renal), NCI-H460 (non-small cell
lung cancer cells), PC-3 (prostate) and OVCAR-03 (ovarian)] were
kindly provided by Frederick Ma (National Cancer Institute,
Bethesda, MD, USA). Additionally, the HaCaT (human keratino-
cytes) cell line was used, a kind donation from Dr. Ricardo Della
Coletta (FOP, UNICAMP). Stock and experimental cultures were
grown in medium containing 5 mL RPMI 1640 (GIBCO BRL) supple-
mented with 5% fetal bovine serum (GIBCO BRL). Penicillin/strep-
tomycin mixture (1000 U/mL:1000 lg/mL, 1 mL/L RPMI) was
added to the experimental cultures. Cells in 96-well plates
(100 lL cells well1) were exposed to sample concentrations in
DMSO/RPMI (0.25, 2.5, 25, 250 lg mL1) at 37 C and incubated
in a 5% CO2 atmosphere for 48 h. The ﬁnal DMSO concentration
did not affect cell viability. Before (T0 plate) and after the sample
addition (T1 plates), cells were ﬁxed with 50% trichloroacetic acid,
and cell proliferation was determined by spectrophotometric
quantiﬁcation (540 nm) of cellular protein using the sulforhoda-
mine B assay. Using the dose–response curve for each cell line,
total growth inhibition (TGI, the concentration that produces total
growth inhibition or cytostatic effects) was determined through
non-linear regression analysis using ORIGIN software version 8.0
(OriginLab Corporation) (Shoemaker, 2006).19
Acknowledgments
The authors are thankful for the ﬁnancial support and fellow-
ships from the Coordenação de Aperfeiçoamento de Pessoal de
Nível Superior (CAPES/Brazil), the Fundação de Apoio à Pesquisa
do Estado do Rio Grande do Sul (PRONEM-FAPERGS/Brazil), and
the Conselho Nacional de Desenvolvimento Cientíﬁco e Tecnológi-
co (CNPq/Brazil).
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bmc.2014.11.019.
References and notes
1. American Cancer Society In Cancer Facts & Figure 2013. http://
www.cancer.org/research/cancerfactsﬁgures/cancerfactsﬁgures/cancer-facts-
ﬁgures-2013.
2. De Petrocellis, L.; Melck, D.; Bisogno, T.; Di Marzo, V. Chem. Phys. Lipids 2000,
108, 191.
3. Bifulco, M.; Laessa, C.; Pisanti, S.; Gazzero, P. Brit. J. Pharmacol. 2006, 148, 123.
4. Persidis, A. Nat. Biotechnol. 1999, 17, 94.
5. Gillet, J. P.; Gottesman, M. M. Methods Mol. Biol. 2010, 596, 47.
6. Farrell, E. K.; Merkler, D. J. Drug Discovery Today 2008, 13, 558.
7. Ezzili, C.; Otrubova, K.; Boger, D. L. Bioorg. Med. Chem. Lett. 2010, 20, 5959.
8. Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Melck, D.; Martin, B. R. Curr. Med.
Chem. 1999, 6, 721.
9. Boger, D. L.; Patterson, J. E.; Guan, X.; Cravatt, B. F.; Lerner, R. A.; Gilula, N. B.
Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4810.
10. Burstein, S.; Salmonsen, R. Bioorg. Med. Chem. 2008, 16, 9644.
11. Sarfaraz, S.; Adhami, V. M.; Syed, D. N.; Afaq, F.; Mukhtar, H. Cancer Res. 2008,
68, 339.
D.S. dos Santos et al. / Bioorg. Med. Chem. 23 (2015) 340–347 34712. (a) Massi, P.; Valenti, M.; Solinas, M.; Parolaro, D. Cancers 2010, 2, 1013; (b)
Grimaldi, C.; Capasso, A. Curr. Med. Chem. 2011, 18, 1575; (c) Proto, M. C.;
Gazzerro, P.; Di Croce, L.; Santoro, A.; Malﬁtano, A. M.; Pisanti, S.; Laezza, C.;
Bifulco, M. J. Cell. Physiol. 2012, 227, 250; (d) Pertwee, R. G.; Howlett, A. C.;
Abood, M. E.; Alexander, S. P. H.; Di Marzo, V.; Elphick, M. R.; Greasley, P. J.;
Hansen, H. S.; Kunos, G.; Mackie, K.; Mechoulam, R.; Ross, R. A. Pharmacol. Rev.
2010, 62, 588.
13. (a) Maccarrone, M.; Lorenzon, T.; Bari, M.; Melino, G.; Finazzi-Agrò, A. J.
Biol. Chem. 2000, 41, 31938; (b) De Petrocellis, L.; Bisogno, T.; Ligresti, A.;
Bifulco, M.; Melck, D.; Di Marzo, V. Fundam. Clin. Pharmacol. 2002, 16,
297; (c) Farsandaj, N.; Ghahremani, M. H.; Ostad, S. N. J. Environ. Pathol.
Toxicol. Oncol. 2012, 31, 377; (d) Fusi, C.; Materazzi, S.; Minocci, D.;
Maio, V.; Oranges, T.; Massi, D.; Nassini, R. J. Invest. Dermat. 2014, 134,
2408.14. D’Oca, C. R. M.; Marinho, T. G.; Hack, C. R. L.; Duarte, R. C.; D’Oca, M. G. M.;
Coelho, T.; Silva, P. A. Bioorg. Med. Chem. Lett. 2010, 20, 525.
15. Lopes, C. R.; D’Oca, C. R. M.; Duarte, R. C.; Kurz, M. H. S.; Primel, E. G.;
Clementin, R. M.; Villarreyes, J. A. M.; D’Oca, M. G. M. Quim. Nova 2010, 33,
1335.
16. Rodrigues, M. O.; Cantos, J. B.; D’Oca, C. R. M.; Soares, K. L.; Coelho, T. S.;
Piovesan, L. A.; Russowsky, D.; Silva, P. A.; D’Oca, M. G. M. Bioorg. Med. Chem.
2013, 21, 6910.
17. Duarte, R. C.; Ongaratto, R.; Piovesan, L. A.; Lima, V. R.; Soldi, V.; Merlo, A. A.;
D’Oca, M. G. M. Tetrahedron Lett. 2012, 53, 2454.
18. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose,
C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.;
Mayo, J.; Boyd, M. J. Natl Cancer Inst. 1991, 83, 757.
19. Shoemaker, R. H. Nat. Rev. Cancer 2006, 6, 813.
